Plain-English translation of NCT05307744 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial investigated whether Lactobacillus plantarum PS128, a type of probiotic (beneficial bacteria), could help improve symptoms in children with autism spectrum disorder. Researchers believe this medication may affect brain chemistry through the gut-brain connection. The study compared children taking the medication with those taking a placebo (inactive pill) over 12 weeks.
Some research suggests that probiotics may influence brain function and neurotransmitter levels, which could potentially help with autism-related social, communication, and behavioral challenges. This trial aimed to test whether this treatment could offer a new supportive option for children with autism.
If you qualified, you would take either the probiotic or a placebo capsule once daily for 12 weeks—two capsules per dose. You would likely have visits with the research team to assess how the treatment is working and any changes in symptoms. The study also included a healthy control group of children without autism for comparison purposes.
AI-generated summary from trial data · Aug 27, 2026 · Not medical advice
Taiwan
Collaborators
Bened Biomedical Co., Ltd.
Enrollment target
~41 participants
Started
July 2022
Primary completion
April 2024
Age range
7 Years – 12 Years
Last updated on clinicaltrials.gov in October 2026.